QPT Quest PharmaTech Inc.

0.0140USD0.0200 CAD · TSXV0.00%Mkt Cap: 2.36M USDP/E: 0.67

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company i…

Key Statistics

Company
Market Cap2.36M USD
Enterprise Value3.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)3.49M USD
Revenue/Share—
Last Price0.0140 USD
Fiscal Year EndJan 2026
MR QuarterJul 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA74836M1068
Valuation
P/E (Trailing)0.67
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.13
EPS (TTM)0.02 USD
EPS (Forward)—
52W Range
0.01400% of range0.0350
52W High0.0350 USD
52W Low0.0140 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE18.91%
ROA18.01%
ROIC-2.59%
ROCE-2.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-133.32K USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.42%
Net Debt641.13K USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio0.06
Quick Ratio0.06
Book Value/Sh0.11 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield42.21%
Payout Ratio0.00%
Ex-Div DateJul 21, 2005
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.169.13M
Float138.70M
Insiders15.02%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short146
Short (prev mo.)541
Technical
SMA 500.0169 (-17.4%)
SMA 2000.0204 (-31.6%)
Beta-0.46
S&P 52W Chg12.00%
Avg Vol (30d)10.83K
Avg Vol (10d)18.11K
Technical Indicators
RSI (14)39.9
MACD-0.0006
MACD Signal-0.0002
MACD Hist.-0.0005
BB Upper0.0213 USD
BB Middle0.0156 USD
BB Lower0.0098 USD
BB Width74.21%
ATR (14)0.0008 USD
Vol Ratio (20d)0.08x

About Quest PharmaTech (CVE: QPT)

›

Quest PharmaTech (CVE: QPT) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.0200 CAD on 18 November 2026, down 50.0% over 52 weeks. Its 52-week range is 0.0200 CAD to 0.0500 CAD, and it trades at the bottom of that range.

Its market capitalisation is 3.38M CAD.

Quest PharmaTech reports return on equity of 18.9% and an operating margin of 0.0%.

Its debt exceeds its cash by 917.15K CAD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 31 May 2027.